How do participants in clinical trials compare with other patients with schizophrenia?

Contemporary Clinical Trials Communications

Jacki L. Stansfeld¹  Joanna Moncrieff²  Robert Freudenthal³  Stefan Priebe⁴  Louise Marston⁵ 

[1] Priment Clinical Trials Unit, University College London, London, UK;;Research &Barnet Enfield Haringey Mental Health NHS Trust, UK;Division of Psychiatry, University College London, London, UK;Research Department of Primary Care and Population Health, University College London, London, UK;

关键词: Clinical trials;    Psychosis;    Schizophrenia;    Antipsychotics;   

DOI  :  

来源: DOAJ

【 摘 要 】

We aimed to explore the clinical relevance of a multicentre, pragmatic randomised trial of antipsychotic reduction in people diagnosed with schizophrenia or psychosis The sample recruited for the antipsychotic reduction study (n = 69 people) was compared with the population of patients with an eligible diagnosis undergoing treatment in the same service (n = 3067 people), using routinely-collected, anonymised data. The trial sample was found to resemble the wider population in terms of the number of past admissions, the likelihood of having been subject to legal detention and the level of risk the patient was perceived to pose to themselves or others. There was a lower proportion of people from minority ethnic backgrounds in the trial sample. The results provide some reassurance that trial recruits were similar to the wider population in terms of the severity of their condition and did not comprise a highly select sample of people with milder problems. The different ethnic composition of the research sample is consistent with other research.

【 授权许可】

Unknown